Atika Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Atika Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.9M	Buy	+104,000	New	+$8.94M	0.78%	34
2025 Q4	–	Sell	-81,300	Closed	-$4.6M	–	98
2025 Q3	$4.6M	Sell	81,300 -65,300	-45%	-$2.95M	0.37%	62
2025 Q2	$6.4M	Buy	+146,600	New	+$5.05M	0.64%	42
2025 Q1	–	Sell	-136,500	Closed	-$5.49M	–	80
2024 Q4	$5.49M	Buy	136,500 +39,500	+41%	+$1.78M	0.58%	61
2024 Q3	$4.59M	Buy	97,000 +5,000	+5%	+$221K	0.47%	63
2024 Q2	$2.75M	Sell	92,000 -10,000	-10%	-$346K	0.27%	77
2024 Q1	$4.1M	Buy	+102,000	New	+$3.65M	0.4%	73

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Atika Capital Management's KYMR Position: Q2 2026 in Review

Atika Capital Management opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 104,000 shares worth $11.9M. The stake represents 0.78% of the portfolio and ranks #34 among its holdings. This is a return to the name: Atika Capital Management previously reported a position in KYMR as recently as Q3 2025.

Atika Capital Management first reported a position in KYMR in Q1 2024 and has held it in 7 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Atika Capital Management held 104,000 shares of Kymera Therapeutics worth $11.9M as of Q2 2026.
Kymera Therapeutics was a new Atika Capital Management position in Q2 2026.
Kymera Therapeutics made up 0.78% of Atika Capital Management's portfolio in Q2 2026, its #34 holding.
Atika Capital Management first reported a position in Kymera Therapeutics in Q1 2024 and has held it in 7 quarters since.
277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.